NRAS is mutated in 15–30% of cutaneous melanoma, and patients having NRAS mutations in melanoma are generally older (>55 years), have thicker tumors, and have inferior clinical outcomes in comparison to patients harboring BRAF mutations [108]. This evidence concerns the gene NRAS and melanoma.